|Bid||7,022.00 x 0|
|Ask||7,024.00 x 0|
|Day's Range||7,011.25 - 7,104.00|
|52 Week Range||5,130.00 - 8,191.30|
|Beta (5Y Monthly)||0.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul. 28, 2020|
|Forward Dividend & Yield||2.03 (2.85%)|
|Ex-Dividend Date||Apr. 16, 2020|
|1y Target Est||7,085.56|
Even if it's not a huge purchase, we think it was good to see that Christopher Sinclair, the Independent Chairman of...
Dividend paying stocks like Reckitt Benckiser Group plc (LON:RB.) tend to be popular with investors, and for good...
In February, Reckitt had announced plans to spend 2 billion pounds over the next three years to spur growth. Reckitt said its business was more resilient now than a few months ago and it was adjusting quickly to a world where personal hygiene was becoming more important. Laxman Narasimhan, who joined as CEO in September, said that he expected more pronounced changes in consumer behaviour the longer people are forced to sit at home.
The U.S. death toll and COVID-19 cases climbed, as arguments flared over coronavirus treatments and the path to restarting the economy.
Doctors and health experts urged people not to drink or inject disinfectant on Friday after U.S. President Donald Trump suggested scientists should investigate inserting the cleaning agent into the body as a way to cure COVID-19. "You may not die of COVID-19 after injecting disinfectant, but only because you may already be dead from the injection." Trump said at his daily media briefing on Thursday that scientists should explore whether inserting light or disinfectant into the bodies of people infected with the new coronavirus might help them clear the disease.
Reckitt Benckiser Group plc (LON:RB.) is about to trade ex-dividend in the next 3 days. You will need to purchase...
The maker of Lysol and Dettol disinfectants said it has already obtained a strain of the novel coronavirus, known as SARS-CoV-2, from an independent lab and plans to use the strain to test whether its products kill the virus. In 2012, for instance, when MERS-coronavirus was a major public health concern, cleaning products had to prove they could kill 9,999 out of 10,000 MERS-Coronavirus cells, according to the agencies’ requirement. COVID-19, the disease caused by novel coronavirus, originated in Wuhan, China, and has spread to more than 100 countries across the world.
The British maker of Durex condoms and Strepsils lozenges reported like-for-like 2019 sales growth of 0.8%, in line with guidance but lagging peers including Procter & Gamble <PG.N> which is targeting underlying growth of 3-5%. Reckitt bought Mead Johnson for about 13 billion pounds in 2017, betting on the rising demand for branded baby formula products in developing markets, especially China.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Could Reckitt Benckiser Group plc (LON:RB.) be an attractive dividend share to own for the long haul? Investors are...
Mothers will also have the option to take a further six months of leave without pay. The Durex condom and Lysol disinfectant maker also said it would increase paid paternity leave for fathers and partners to four weeks, with the option to take a further four weeks of leave without pay. Reckitt Benckiser has also launched suites for breastfeeding mothers returning to work and free breast pumps if needed.
Investors who take an interest in Reckitt Benckiser Group plc (LON:RB.) should definitely note that the Chief...
The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.
The FTSE 100 added 0.7%, with BP and Shell both gaining more than 2% and Asia-focussed HSBC also rising after China signalled progress in trade talks with the United States. Other standouts in the index, whose components book most of their earnings abroad, were AstraZeneca and BAT, while Durex condom maker Reckitt pared losses despite cutting its sales view for the second time this year. British Prime Minister Boris Johnson told parliament that if it delayed his legislation to leave the European Union he would abandon his attempt to ratify the deal and push for an election instead, threatening further political turmoil.
Reckitt Benckiser's <RB.L> new chief executive promised on Tuesday to step up spending on its brands and improve performance after the British household goods maker cut its full-year sales forecast for a second time. "We are not pleased with where we are and we must consistently deliver," Laxman Narasimhan, who took over from long-time CEO Rakesh Kapoor in September, said on his first call with the investment community. Narasimhan particularly lamented the performance of the firm's Health business, its largest, where a failed product launch, the nearly $17 billion acquisition of Mead Johnson, and a temporary baby milk factory shutdown in the Netherlands, have all caused significant disruption, some lasting to this day.
The maker of Durex condoms and Lysol disinfectant said on Monday that Carr, who has been finance chief at Dutch-American supermarket operator Ahold since 2011, would bring "extensive experience across consumer and retail companies". The appointment of Carr, who worked for Reckitt between 1994 and 2004, is its second big management change this year after replacing long-time chief executive Rakesh Kapoor with PepsiCo <PEP.O> executive Laxman Narasimhan as CEO.
The big shareholder groups in Reckitt Benckiser Group plc (LON:RB.) have power over the company. Insiders often own a...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
The blue-chip index followed Wall Street lower after U.S. President Donald Trump warned China not to wait for the 2020 U.S. presidential election to make a trade deal. Big British banks, such as Barclays <BARC.L> and RBS <RBS.L>, fell after the BoE said banks would have to tell investors in 2021 if they could be closed down without disrupting financial markets. Corporate earnings were the main drivers behind most of the major stock moves on both UK indexes.
Reckitt Benckiser <RB.L> cut its full-year revenue target after reporting lower than expected sales in its last quarter under long-time chief executive Rakesh Kapoor, hurt by a surprise slowdown in demand for infant formula in China. The Durex condom and Lysol disinfectant maker said on Tuesday it now expected full-year like-for-like sales growth of between 2% and 3%, down from its previous target of 3% to 4%, also blaming a tough market in Europe for its downgrade. Reckitt, which kept its "broadly flat" operating margin target, said slowing birth rates over the past two years and increased competition had led to market share losses for its Enfamil infant nutrition products in China, its biggest market for baby food.
Germany's Bayer <BAYGn.DE> signed a deal on Monday to sell its Dr. Scholl's footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million (£469.31 million), the second of two consumer care products it had put on the block. Bayer, whose stock has slumped amid lawsuits over an alleged cancer-causing effect of its Roundup weed killer, struck a deal in May to sell U.S. sun care brand Coppertone to Nivea maker Beiersdorf <BEIG.DE> for $550 million. The divestments are part of a wider overhaul unveiled in November by Bayer Chief Executive Werner Baumann, who is under pressure to boost the share price.
The FTSE 100 <.FTSE> shed 0.3%, while the mid-cap FTSE 250 <.FTMC> capitalised on a rise in sterling to add 0.1%. The U.S. government scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. "Overall, we view this outcome as a modest negative for the major pharmaceutical group," JP Morgan analysts wrote, adding that the move had removed a "potential positive catalyst" for the sector.
The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.